Greater Cannabis Company Reports Increased Losses and No Revenue in Q1 2025 Financial Update

The Greater Cannabis Company, Inc. (OTCBB: GCAN) has released its quarterly financial report for the period ending March 31, 2025. Here’s a summary of the company's performance, highlighting both positive and negative aspects from the income statement.

Key Financial Highlights:

• Revenue: The company reported no revenue in both Q1 2025 and Q1 2024.
• Operating Expenses: Increased from $38,951 in Q1 2024 to $43,536 in Q1 2025.
• Net Loss: Grew to $103,511 in Q1 2025 from $44,611 in Q1 2024.
• Cash Position: Cash decreased from $57,368 at the end of December 2024 to $46,213 at the end of Q1 2025.
• Weighted Average Shares Outstanding: Increased from 732,638,436 to 910,373,303 shares.
• Accumulated Deficit: Increased to $(4,763,856) from $(4,660,345).

Positive Aspects:

• The company continues to engage in R&D for cannabinoid therapeutics, recently moving forward with clinical studies related to new therapies for neuropsychiatric disorders.
• Management has solid strategic plans focusing on cannabis-related investment opportunities through partnerships and licensing agreements.
• The overarching aim is to amplify market presence, particularly in the therapeutic segment.

Negative Aspects:

• Continued inability to generate revenue raises concerns about operational viability. The company has not earned revenue for several periods.
• The increase in net loss and operating expenses indicates financial strain and increased costs without corresponding revenue generation.
• Debt obligations, including substantial loans from related parties, mean the company may face liquidity challenges without significant funding or operational changes.

Outlook: The Greater Cannabis Company needs to focus on generating revenue through its therapeutic initiatives and seek additional financing to stabilize its operations. The challenges of increased losses and lack of sales underscore the importance of strategic execution for future growth.